#ASCO14: Patients Should Be at the Center of the Value Proposition

05.31.14 | By

Yesterday, ASCO held a panel entitled, “Can We Find Common Ground? Stakeholder Perspectives on Value in Cancer.” At the tail end, a woman stepped to the mike to make an observation to the panelists. Describing herself as a patient and an advocate, she declared that she heard little in the presentations about patient-reported outcomes, particularly in reference to ASCO's value initiative that is in the works.

 

Castellani Op-Ed in The Hill: Health insurance model must evolve

05.31.14 | By

In case you missed it, The Hill featured an op-ed by PhRMA President and CEO John J. Castellani, “Health insurance model must evolve,” to coincide with the start of the American Society of Clinical Oncology’ (ASCO) 50th anniversary conference.

Week in Review: The Price of Innovation & Patient Well-Being

05.30.14 | By

The cost of innovative new medicines to treat devastating diseases such as cancer and Hepatitis C has been a hot discussion topic this week. A critical part of this discussion – the value of these treatments – however, has been overlooked. As our President and CEO John Castellani said, focusing solely on the cost of a new treatment and ignoring its subsequent value is “penny wise and pound foolish” because prescription medicines provide patients and the health care system long-term cost savings.

PhRMA Statement on FDA Draft Guidance on Labeling for Products Approved Under the Accelerated Approval Pathway

Washington, D.C. (May 30, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement on the Food and Drug Administration (FDA) draft guidance on labelling for human prescription drug and biologics approved under the Accelerated Approval pathway:

Achieving the shared goal of bringing safe and effective new medicines to patients

05.30.14 | By

Each patient facing a life-threatening disease lives with the hope that tomorrow will bring a new medicine to extend and improve his or her life.  As a scientist, a new father, and as someone who lost a parent to stage IV lung cancer far too early in life, it is gut-wrenching to admit that modern drug development continues to be a highly challenging and far too often unsuccessful endeavor. 

Transforming Healthcare One Employee at a Time

05.30.14 | By

Businesses know the impact of poor health and see first hand how some communities are affected more than others. Truly improving health takes time, effort and investment from all of us. With one out of two Americans having at least one chronic condition, the costs of chronic disease are staggering and affect every community, every business, and every person.

The Global Impact of Innovative Medicines

05.23.14 | By

Across our health care system, it’s critical that patients always remain at the center of our shared efforts to improve, extend and save lives. For PhRMA and the industry writ-large, this is a bedrock mindset and ongoing access to innovative medicines represents health care’s best shot at preventing and managing costly chronic diseases. This week, we focused on the importance of patient access – along with safety – both in the United States and around the globe.

Vaccines’ Important Role in Improving Quality of Life

05.23.14 | By

Through innovative immunization practices, smallpox has been eradicated, polio and measles have nearly been eradicated and diseases like hepatitis A and B and some forms of cancer have been prevented. Vaccines have profoundly impacted patient health, and while their success has been life altering for millions of people around the world, there is still progress to be made.

Breaking the Stigma Can Do Wonders for the Understanding and Treatment of Mental Illness

05.23.14 | By

Mental illness, whether we realize it or not impacts us all. 61.5 million Americans or one in four has a mental illness. The statistics can be alarming when you take a deeper look: One in 20 U.S. children has ADHD, 21 million American adults currently suffer from depression, and 40 million Americans have some type of anxiety disorder. But there is hope.

Rethinking Coverage and Access In Health Care – Hepatitis C

05.22.14 | By

Hepatitis C impacts an estimated 3.2 million Americans. Between 60 and 70% of those with hepatitis C develop chronic liver disease, between 5 and 20% will eventually develop cirrhosis, and an estimated 12,000 die from hepatitis C related illness each year.

Pages

Subscribe to RSS - Opinion